The increasing frequency of fungal infections in immunocompromised patients together with the emergence of strains resistant to currently used antifungal drugs point to an increased need for a new class of antimycotics. Antimicrobial peptides are promising candidates for the treatment of fungal infections since they have both mechanisms of action distinct from available antifungal agents and the ability to regulate the host immune defence systems as well. This review focuses on Candida albicans as a large amount of work on the mechanisms of action of classical antifungals as well as antimicrobial peptides, such as defensins, protegrins, histatins and lactoferrin (LF)-derived peptides, has been performed in this yeast. Analogues of these antimicrobial peptides and combinations of antimicrobial peptides with classical antimycotics are under investigation for treatment of candidiasis.

Antimicrobial peptides: therapeutic potential for the treatment of Candida infections / A. Lupetti, R. Danesi, V. J. W., V. J. T., S. Senesi, N. P. H.. - In: EXPERT OPINION ON INVESTIGATIONAL DRUGS. - ISSN 1354-3784. - 11:2(2002), pp. 309-318. [10.1517/13543784.11.2.309]

Antimicrobial peptides: therapeutic potential for the treatment of Candida infections

R. Danesi;
2002

Abstract

The increasing frequency of fungal infections in immunocompromised patients together with the emergence of strains resistant to currently used antifungal drugs point to an increased need for a new class of antimycotics. Antimicrobial peptides are promising candidates for the treatment of fungal infections since they have both mechanisms of action distinct from available antifungal agents and the ability to regulate the host immune defence systems as well. This review focuses on Candida albicans as a large amount of work on the mechanisms of action of classical antifungals as well as antimicrobial peptides, such as defensins, protegrins, histatins and lactoferrin (LF)-derived peptides, has been performed in this yeast. Analogues of these antimicrobial peptides and combinations of antimicrobial peptides with classical antimycotics are under investigation for treatment of candidiasis.
Anti-Bacterial Agents; therapeutic use; Antifungal Agents; therapeutic use; Candida albicans; drug effects; Candidiasis; drug therapy; Defensins; therapeutic use; Humans; Lactoferrin; analogs /&/ derivatives/therapeutic use; Proteins; therapeutic use
Settore BIOS-11/A - Farmacologia
2002
Article (author)
File in questo prodotto:
File Dimensione Formato  
preprint Exp Opin Invest Drugs.pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 8.91 MB
Formato Adobe PDF
8.91 MB Adobe PDF Visualizza/Apri
danesi2002.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 199.08 kB
Formato Adobe PDF
199.08 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1104069
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 61
  • ???jsp.display-item.citation.isi??? 55
  • OpenAlex ND
social impact